Barclays Lowers Sotera Health (NASDAQ:SHC) Price Target to $16.00

Sotera Health (NASDAQ:SHC) had its price objective lowered by equities research analysts at Barclays from $17.00 to $16.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target would suggest a potential upside of 28.31% from the stock’s current price.

SHC has been the subject of a number of other research reports. Citigroup increased their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. The Goldman Sachs Group started coverage on Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Sotera Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.92.

Sotera Health Trading Up 1.5 %

Sotera Health stock traded up $0.19 during midday trading on Friday, reaching $12.47. The stock had a trading volume of 1,816,518 shares, compared to its average volume of 979,003. The stock has a market capitalization of $3.53 billion, a PE ratio of 49.88 and a beta of 1.91. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The stock’s 50-day simple moving average is $13.46 and its 200 day simple moving average is $14.52. Sotera Health has a twelve month low of $10.71 and a twelve month high of $17.08.

Institutional Trading of Sotera Health

Several institutional investors have recently added to or reduced their stakes in SHC. Darsana Capital Partners LP increased its position in shares of Sotera Health by 716.9% in the 3rd quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock worth $334,167,000 after purchasing an additional 17,560,636 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Sotera Health by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company’s stock worth $204,154,000 after acquiring an additional 173,341 shares in the last quarter. Sessa Capital IM L.P. grew its position in shares of Sotera Health by 46.5% in the 3rd quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after acquiring an additional 2,000,000 shares in the last quarter. Sculptor Capital LP acquired a new stake in shares of Sotera Health during the 4th quarter valued at approximately $68,400,000. Finally, State Street Corp lifted its stake in Sotera Health by 18.5% during the third quarter. State Street Corp now owns 4,126,806 shares of the company’s stock worth $68,918,000 after purchasing an additional 644,236 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.